期刊文献+

活化白细胞黏附分子、癌胚抗原相关细胞黏附分子在非小细胞肺癌组织中的表达及对预后影响 被引量:6

Expression of ALCAM and CEACAM-6 in non-small cell lung cancer and their relationship with prognosis
下载PDF
导出
摘要 目的探讨活化白细胞黏附分子(activated leukocyte cell adhesion molecule,ALCAM)和癌胚抗原相关细胞黏附分子(carcinoembryonic antigen-related cell adhesion molecule,CEACAM)在非小细胞肺癌组织中的表达及与患者临床病理特征及预后的相关性。方法免疫组织化学及实时定量荧光聚合酶链反应(real-time,PCR)检测ALCAM、CEACAM-6在46例肺癌及癌旁组织中的表达;分析ALCAM,CEACAM-6及临床各指标与预后的关系。结果 ALCAM和CEACAM-6在癌组织中的表达明显高于癌旁组织;其中ALCAM在鳞癌组织中阳性表达率100%,在腺癌组织中阳性表达率56%,差异有统计学意义(P<0.05),且ALCAM,CEACAM-6在T1期患者肿瘤组织中的表达显著高于T2+T3期,差异有统计学意义(P<0.05)。ALCAM和CEACAM-6蛋白表达与肿瘤患者年龄、性别、淋巴结转移生存期差异无统计学意义(P>0.05)。ALCAM和CEACAM-6在非小细胞肺癌组织中呈现正相关,且阳性表达患者预后优于阴性表达患者。结论 ALCAM、CEACAM-6蛋白在非小细胞肺癌组织中高表达,并可能与患者预后相关。 Objective To investigate the expression levels of activated leukocyte cell adhesion molecule (ALCAM) and carcino-embryonic antigen related cellular adhesion molecule-6 (CEACAM-6) and their relationship with prognosis in patients with non-small cell lung cancer (NSCLC) as well as their clinicopathologic significance. Methods Immunohistochemical and RT-PCR methods were used to detect the expression of ALCAM and CEACAM-6 in 46 NSCLC specimens. The relationship between the expression of ALCAM and CEACAM 6 and clinicopathological features was statistically analyzed. Results The expression of both ALCAM and CEACAM-6 were significantly higher in NSCLC than in adjacent tissues, including 100% positive rate of ALCAM in squamous cell carcinoma and 56% positive rate of ALCAM in adenocareinoma ( P 〈 0.05). How the expression of ALCAM and CEACAM-6 was significantly higher in stage T1 than in stage T2 and T3 ( P d0.05). There were no significant correlation between the protein expression of ALCAM and CEACAM-6 and the age, gender, tumor classification, lymphatic metastasis, pathological stage or lifetime ( P 〉0.05). A positive correlation of the expression of ALCAM with CEACAM-6 was found in NSCLC, and the prognosis of patients with NSCLC was significantly better in positive expression of ALCAM and CEACAM-6. Conclusion ALCAM and CEACAM-6 were highly expressed in NSCLC, and may correlate to prognosis.
出处 《临床荟萃》 CAS 2015年第8期870-874,共5页 Clinical Focus
基金 国家自然科学基金资助项目(81370372)
关键词 非小细胞肺 活化白细胞黏附分子 细胞黏附分子 预后 carcinoma, non-small-cell lung activated-leukocyte cell adhesion molecule cell adhesionmolecules prognosis
  • 相关文献

参考文献14

  • 1钟立,张秉强.活化白细胞黏附分子与肿瘤[J].黑龙江医学,2014,38(7):745-747. 被引量:4
  • 2杨长成,王文涓,高锋.癌胚抗原相关黏附分子1与肿瘤[J].检验医学,2014,29(9):877-883. 被引量:10
  • 3Maurizi G, Rendina EA. Bronchovascular reconstructions for lung cancer., improvements over time[J]. Eur J Cardiothorac Surg,2015 Mar 13. [Epub ahead of print].
  • 4Burandt E, Bari Noubar T, Lebeau A,et al. Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2, 197 breast cancer patients[J]. Oncology reports, 2014, 32 (6) : 2628-2634.
  • 5Fagotto F. Regulation of cell adhesion and cell sorting at embryonic boundaries[J]. Curt Top Dev Biol, 2015,112:19- 64.
  • 6Hooker RA, Chitteti BR, Egan PH,et al. Activated leukocyte cell adhesion molecule (ALCAM or CD166) modulates bone phenotype and hematopoiesis[J]. J Musculoskelet Neuronal Interact, 2015,15 ( 1 ) .- 83-94.
  • 7Lee K, Hong J, Kim K,et al. The role of activated leukocyte cell adhesion molecule (alcam/cd166) in the pathogenesis of asthma[J]. Am J Respir Crit Care Med, 2015, 191:A5180.
  • 8Wallentin L, Michelsen AE, Aukrust P, et al. Activated leukocyte cell adhesion molecule (alcam) and outcomes in acute coronary syndromes: a plato biomarker substudy[J]. J Am Coil Cardiol, 2015, 65(10 S).
  • 9Jezierska A, Matysiak W, Motyl T. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy[J]. Med Sci Monit, 2006, 12(8):BR263 273.
  • 10Tachezy M, Zander H, Wolters-Eisfeld G, et al. Activated leukocyte cell adhesion molecule (CD166 ) : an " inert" cancer stem cell marker for non-small cell lung cancer [J]. Stem Cells, 2014, 32(6) :1429-1436.

二级参考文献4

共引文献12

同被引文献71

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin,2010,60(5):277-300.
  • 2Arigami T, Uenosono Y, Ishigami S, et al. Expression of stanniocalcin 1 as a potential biomarker of gastric cancer[J]. Oncology, 2012,83(3) : 158-164.
  • 3Jiang HG, Li J, Shi SB, et al. Value of fibrinogen and D, dimer in predicting recurrence and metastasis after radical surgery for non-small cell lung cancer[J]. Med Oncol, 2014,31 (7):22.
  • 4Arigami T, Okumura H, Matsumoto M, et al. Analysis of the fibrinogen and neutrophil-lymphocyte ratio in esophageal squamous cell carcinoma., a promising blood marker of tumor progression and prognosis[J]. Medicine (Baltimore), 2015,94 (42) : e1702.
  • 5Arigami T, Uenosono Y, Matsushita D, et al. Combinedfibrinogen concentration and neutrophil-lymphocyte ratio as a prognostic marker of gastric cancer[J]. Oncol Lett, 2016, 11(2) : 1537-1544.
  • 6Zhang B, Song Y, Jin J, et al. Preoperative plasma fibrinogen level represents an independent prognostic factor in a Chinese cohort of patients with upper tract urothelial carcinoma[J]. PLoS One,2016,11(3) :e150193.
  • 7Pinato DJ, Shiner RJ, Seckl MJ, et aL Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer[J]. Br J Cancer, 2014,110(8): 1930-1935.
  • 8Cho IR, Park JC, Park CH, et al. Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric eancer[J]. Gastric Cancer, 2014,17 (4) : 703- 710.
  • 9Marinho FC, Takagaki TY. Hypercoagulability and lung cancer[J]. J Bras Pneumol,2008,34(5) :312-322.
  • 10Sorensen B, Larsen OH, Rea CJ, et al. Fibrinogen as a hemostatic agent [J]. Semin Thromb Hemost, 2012, 38 (3) : 268-273.

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部